‘Artificial pancreas’ may be option for diabetics

Scientists have used an “artificial pancreas” system of pumps and monitors to improve blood sugar control in diabetes patients in the first study to show the new device works better than conventional treatment.

Researchers from Britain’s Cambridge University tested the device on 17 children with type 1 diabetes during a series of nights in hospital and found it kept their blood sugar levels within the important “normal” range for 60 percent of the time.

The new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.

Medical device makers have been working for years to develop a so-called artificial pancreas to deliver insulin to patients with type 1 diabetes, an autoimmune disease in which the body destroys its own ability to make insulin.

The bodies of type 1 diabetes sufferers become unable to properly break down sugar and if untreated, blood vessels and nerves are destroyed, organs fail and patients die.

“These devices could transform the management of type 1 diabetes, but it is likely to be a gradual process,” Roman Hovorka of Cambridge, who led the research, said in a telephone interview.

He said the results were “an important stepping stone” toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.

“It’s a bit like with mobile phones. When we started, the technology wasn’t very good and the functionality was limited, and it took a number of generations to move to the device that we have now. I see the same thing with this system.”

The Juvenile Diabetes Research Foundation said last month it was teaming up with U.S. drugmaker Johnson & Johnson’s unit Animas, which makes insulin pumps, and DexCom Inc, which makes continuous glucose monitoring devices, to develop and test an artificial pancreas system.

The Cambridge study, published in The Lancet medical journal on Friday, used devices and sensors from Smiths Medical, a unit of Smiths Group, Abbott Diabetes Care, a unit of Abbott Laboratories, and Medtronic.

The ultimate goal is to create a device that can check patients’ blood day and night, during and between meals, and deliver insulin as required.

The Cambridge study found their device performed better than a conventional pump, which delivers insulin at pre-set rates and which kept blood sugar levels around normal for 40 percent of the time compared with 60 percent for the artificial pancreas.

Hovorka said the findings were particularly encouraging because the study included nights when the children went to bed after eating a large evening meal or having done exercise - both of which can affect blood sugar levels.

SOURCE: The Lancet, online February 5, 2010.

RELATED STORIES:
Diabetes’ link to eating disorders explored   New alterations found in young adults with type 2 diabetes   Lunchtime coffee break best for fighting diabetes   A1c diabetes test better indicator of risk: study   Nap lovers show higher diabetes rate   Twice as many women to be diagnosed with gestational diabetes   Stress linked to diabetics’ memory loss   Cholesterol drugs raise diabetes risk, just a bit   Insulin Regulates Beta Cell Function in Healthy Humans   American Association Of Clinical Endocrinologists Approves New Diagnosis For Diabetes   Diabetes patients rank health concerns differently than their doctors, U-M survey shows   Scientists map out regulatory regions of genome, hot spots for diabetes genes

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]